Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2025)

Camp4 Therapeutics' Cash from Financing Activities history spans 3 years, with the latest figure at $28.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 60.88% year-over-year to $28.6 million; the TTM value through Dec 2025 reached $75.9 million, up 5.9%, while the annual FY2025 figure was $75.9 million, 5.9% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $28.6 million at Camp4 Therapeutics, down from $47.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $73.1 million in Q4 2024 and bottomed at -$812000.0 in Q2 2024.
  • The 3-year median for Cash from Financing Activities is -$63000.0 (2023), against an average of $16.4 million.
  • The largest annual shift saw Cash from Financing Activities soared 116071.43% in 2024 before it plummeted 60.88% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at -$63000.0 in 2023, then skyrocketed by 116071.43% to $73.1 million in 2024, then tumbled by 60.88% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Cash from Financing Activities are $28.6 million (Q4 2025), $47.4 million (Q3 2025), and $72000.0 (Q2 2025).